CRISPR Therapeutics AG
Basel · Founded 2013
- Website not added yet
- LinkedIn not added yet
- X not added yet
- Instagram not added yet
- Facebook not added yet
CRISPR Therapeutics AG was founded in 2013 by Kurt J. von Emster, Sven Ante Lundberg, Thomas J. Woiwode, Ali Anthony Behbahani, Rodger Novak, Pablo J. Cagnoni, Bradley Anthony Bolzon, N. Anthony Coles, Kala Ante Subramanian, Samarth Ante Kulkarni, Marc J. Becker, Simeon J. George, Tyler Ante Dylan-Hyde, Lawrence Klein, Ali Behbahani, Samarth Kulkarni, James Kasinger, Bradley Bolzon, Tony Ho, John Greene, Katherine High, Simeon George and Michael Tomsicek, and is based in Basel.
Key facts
- Industry
- Biotechnology
- Legal form
- Incorporated in V8
- Listed
- Nasdaq · CRSP
About
Biological Products, (No Diagnostic Substances); listed on Nasdaq as CRSP; filing with the SEC since 2016
Founders
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer, Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer, Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
In context
We hold 1,386 other biotechnology companies founded in the 2010s. None has a closure on record yet. Of the 1,338 that report what they raised, the median is $4,000,000.
Counted across this directory, from founding and closing years in public records. Medians cover only companies whose closure is recorded; a company with no closure date may have quietly ceased without the record catching it.
Discussion
Log in to join the discussion and like comments.
Log In to Comment